Axovant's Alzheimer's drug fails in late-stage trial, shares slump

(Reuters) - Axovant Sciences Ltd said on Tuesday its experimental Alzheimer's drug failed to improve cognitive abilities and daily activities in a highly anticipated late-stage trial, sending its shares plunging 70 percent in premarket trading.